TOKYO — Japanese drugmaker Eisai will make its Alzheimer’s disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to receive it, with the company planning to later roll out home use in China and India.
“The new formulation will be a game changer in Alzheimer’s treatment,” said CEO Haruo Naito, who revealed the plans to Nikkei.
